See more : Honeywell International Inc. (HON.L) Income Statement Analysis – Financial Results
Complete financial analysis of Kura Oncology, Inc. (KURA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kura Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shenzhen Bauing Construction Holding Group Co., Ltd. (002047.SZ) Income Statement Analysis – Financial Results
- Shofu Inc. (7979.T) Income Statement Analysis – Financial Results
- Jyoti Structures Limited (JYOTISTRUC.BO) Income Statement Analysis – Financial Results
- ATWEC Technologies, Inc. (ATWT) Income Statement Analysis – Financial Results
- PT Sumi Indo Kabel Tbk (IKBI.JK) Income Statement Analysis – Financial Results
Kura Oncology, Inc. (KURA)
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 849.00K | 759.00K | 558.00K | 194.00K | 0.00 | 10.00K | 30.00K | 31.00K | 20.00K | 23.91K | 22.73K | 22.34K | 23.44K | 20.51K | 19.16K | 0.00 |
| Gross Profit | -849.00K | -759.00K | -558.00K | -194.00K | 0.00 | -10.00K | -30.00K | -31.00K | -20.00K | -23.91K | -22.73K | -22.34K | -23.44K | -20.51K | -19.16K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 115.24M | 92.81M | 84.72M | 60.40M | 47.83M | 46.79M | 26.43M | 20.40M | 17.78M | 8.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 50.57M | 47.05M | 46.54M | 31.50M | 19.65M | 16.10M | 9.65M | 7.96M | 6.09M | 3.85M | 22.34K | 23.44K | 20.51K | 20.51K | 19.16K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.57M | 47.05M | 46.54M | 31.50M | 19.65M | 16.10M | 9.65M | 7.96M | 6.09M | 3.85M | 22.34K | 23.44K | 20.51K | 20.51K | 19.16K | 0.00 |
| Other Expenses | 0.00 | 4.03M | 792.00K | 2.27M | 4.34M | 2.44M | 643.00K | 807.00K | 1.24M | 2.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -33.62K |
| Operating Expenses | 165.80M | 139.87M | 131.26M | 91.90M | 67.48M | 62.88M | 36.08M | 28.37M | 23.87M | 10.90M | 22.34K | 23.44K | 20.51K | 20.51K | 19.16K | -33.62K |
| Cost & Expenses | 165.80M | 139.87M | 131.26M | 91.90M | 67.48M | 62.88M | 36.08M | 28.37M | 23.87M | 10.90M | 22.34K | 23.44K | 20.51K | 41.02K | 38.32K | -33.62K |
| Interest Income | 14.72M | 4.25M | 1.21M | 2.80M | 4.67M | 3.17M | 751.00K | 499.00K | 128.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.55M | 229.00K | 414.00K | 578.00K | 580.00K | 970.00K | 888.00K | 577.00K | 88.00K | 5.88K | 4.97K | 3.60K | 1.89K | 1.89K | 838.00 | 0.00 |
| Depreciation & Amortization | 849.00K | 759.00K | 558.00K | 194.00K | 10.00K | 10.00K | 30.00K | 31.00K | 20.00K | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -164.96M | -139.11M | -129.71M | -91.71M | -67.48M | -62.87M | -36.05M | -28.34M | -23.85M | -11.80M | -22.34K | -23.44K | -20.51K | -41.02K | -38.32K | -33.62K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -165.80M | -140.62M | -131.82M | -92.09M | -67.48M | -62.88M | -36.08M | -28.37M | -23.87M | -11.80M | -22.34K | -23.44K | -20.51K | -41.02K | -38.32K | -33.62K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 13.17M | 4.03M | 792.00K | 2.27M | 4.44M | 2.64M | 943.00K | 807.00K | 972.00K | 879.00K | 16.86K | 17.37K | 19.84K | 18.62K | 18.32K | 0.00 |
| Income Before Tax | -152.63M | -135.84M | -130.47M | -89.63M | -63.14M | -60.45M | -35.43M | -27.56M | -22.63M | -11.01M | -27.32K | -27.04K | -22.40K | -22.40K | -20.00K | -33.62K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 229.00K | -558.00K | -194.00K | -10.00 | 3.41M | -30.00K | -31.00K | -20.00K | 268.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -152.63M | -136.07M | -129.91M | -89.43M | -63.14M | -60.45M | -35.43M | -27.56M | -22.63M | -11.01M | -27.32K | -27.04K | -22.40K | -22.40K | -20.00K | -33.62K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.08 | -2.03 | -1.96 | -1.68 | -1.51 | -1.72 | -1.52 | -1.47 | -2.28 | -78.11 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.08 | -2.03 | -1.96 | -1.68 | -1.51 | -1.72 | -1.52 | -1.47 | -2.28 | -78.11 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 73.23M | 66.99M | 66.35M | 53.08M | 41.95M | 35.19M | 23.24M | 18.70M | 9.93M | 141.00K | 5.00M | 5.00M | 5.00M | 5.00M | 5.00M | 0.00 |
| Weighted Avg Shares Out (Dil) | 73.23M | 66.99M | 66.35M | 53.08M | 41.95M | 35.19M | 23.24M | 18.70M | 9.93M | 141.00K | 5.00M | 5.00M | 5.00M | 5.00M | 5.00M | 0.00 |
Kura Oncology to Host Virtual Investor Event on December 9, 2024
Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming JMP Securities Hematology...
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
Kura Oncology said on Wednesday it will collaborate with Japan's Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib.
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit...
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors –
Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Pete De Spain - Head, Investor Relations Dr. Troy Wilson - President and CEO Tom Doyle - Senior Vice President, Finance and...
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th –
Kura Oncology to Report Third Quarter 2024 Financial Results
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2024 financial...
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models –
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
– New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics – – New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics –
Source: https://incomestatements.info
Category: Stock Reports